ISYGRA Trademark

Trademark Overview

On Tuesday, December 27, 2011, a trademark application was filed for ISYGRA with the United States Patent and Trademark Office. The USPTO has given the ISYGRA trademark a serial number of 79108516. The federal status of this trademark filing is IR CANCELLED - US REGISTRATION CANCELLED as of Sunday, August 29, 2021. This trademark is owned by NOVARTIS AG. The ISYGRA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention or treatment of diseases and disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; pharmaceutical preparations for the prevention and treatment of ocular disorders and diseases; pharmaceutical preparations for the treatment of diseases and disorders caused by bacteria, autoimmune diseases and disorders, kidney diseases and disorders, diabetes; antifungal, anti-infective, antiviral preparations and antibiotics
isygra

General Information

Serial Number79108516
Word MarkISYGRA
Filing DateTuesday, December 27, 2011
Status404 - IR CANCELLED - US REGISTRATION CANCELLED
Status DateSunday, August 29, 2021
Registration Number4181509
Registration DateTuesday, July 31, 2012
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 15, 2012

Trademark Statements

Goods and ServicesPharmaceutical preparations for the prevention or treatment of diseases and disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; pharmaceutical preparations for the prevention and treatment of ocular disorders and diseases; pharmaceutical preparations for the treatment of diseases and disorders caused by bacteria, autoimmune diseases and disorders, kidney diseases and disorders, diabetes; antifungal, anti-infective, antiviral preparations and antibiotics

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeH - NOT AVAILABLE
Class Status DateFriday, November 27, 2015
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNovartis AG
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressCH
Party NameNOVARTIS AG
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBasel
CH
Party NameNOVARTIS AG
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBasel
CH

Trademark Events

Event DateEvent Description
Sunday, September 4, 2022NOTIFICATION PROCESSED BY IB
Sunday, February 27, 2022NOTIFICATION PROCESSED BY IB
Thursday, January 20, 2022INTERNATIONAL REGISTRATION RENEWED
Wednesday, September 22, 2021NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Wednesday, September 22, 2021DEATH OF INTERNATIONAL REGISTRATION
Friday, May 22, 2020NOTIFICATION PROCESSED BY IB
Friday, May 15, 2020NOTIFICATION PROCESSED BY IB
Friday, September 20, 2019NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Friday, September 20, 2019DEATH OF INTERNATIONAL REGISTRATION
Friday, December 2, 2016NOTIFICATION PROCESSED BY IB
Friday, December 11, 2015NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Friday, December 11, 2015DEATH OF INTERNATIONAL REGISTRATION
Saturday, April 13, 2013NEW REPRESENTATIVE AT IB RECEIVED
Saturday, February 23, 2013CHANGE OF NAME/ADDRESS REC'D FROM IB
Sunday, November 18, 2012FINAL DECISION TRANSACTION PROCESSED BY IB
Wednesday, October 31, 2012FINAL DISPOSITION NOTICE SENT TO IB
Wednesday, October 31, 2012FINAL DISPOSITION PROCESSED
Wednesday, October 31, 2012FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, July 31, 2012REGISTERED-PRINCIPAL REGISTER
Tuesday, May 15, 2012OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 15, 2012PUBLISHED FOR OPPOSITION
Wednesday, April 25, 2012NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, April 7, 2012LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, April 4, 2012ASSIGNED TO LIE
Saturday, March 24, 2012REFUSAL PROCESSED BY IB
Friday, March 16, 2012APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, March 12, 2012TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, March 12, 2012CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, March 12, 2012TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, March 5, 2012ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, March 5, 2012TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, February 24, 2012NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, February 24, 2012REFUSAL PROCESSED BY MPU
Wednesday, February 22, 2012NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, February 21, 2012NON-FINAL ACTION WRITTEN
Tuesday, February 21, 2012ASSIGNED TO EXAMINER
Tuesday, February 21, 2012APPLICATION FILING RECEIPT MAILED
Thursday, February 16, 2012NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, February 10, 2012LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, February 9, 2012SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

isygra disorders system preparations pharmaceutical diseases treatment prevention caused bacteria ophthalmology